viltolarsen
Selected indexed studies
- Viltolarsen. (, 2012) [PMID:36580569]
- Viltolarsen: First Approval. (Drugs, 2020) [PMID:32519222]
- Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial. (JAMA Neurol, 2020) [PMID:32453377]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Viltolarsen. (2012) pubmed
- Viltolarsen: First Approval. (2020) pubmed
- Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial. (2020) pubmed
- Viltolarsen. (2020) pubmed
- Safety and efficacy of viltolarsen in ambulatory and nonambulatory males with Duchenne muscular dystrophy. (2024) pubmed
- Viltolarsen for the treatment of Duchenne muscular dystrophy. (2019) pubmed
- Viltolarsen: a treatment option for Duchenne muscular dystrophy patients who are amenable to exon 53 skipping therapy. (2023) pubmed
- Evolving Role of Viltolarsen for Treatment of Duchenne Muscular Dystrophy. (2024) pubmed
- Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study. (2023) pubmed
- Viltolarsen: From Preclinical Studies to FDA Approval. (2023) pubmed